Integrative analysis reveals biologically supported drug targets for Alzheimer's disease, highlighting efficacy and safety profiles.
This study established a comprehensive AD target atlas, revealing mechanism-anchored targets that were validated across multiomics analyses and a clinically actionable framework integrating efficacy, biology, and safety profiling. Overall, these results advance AD drug discovery by revealing prioritized targets with causal biological support and providing a validated development roadmap.
No takes yet. Share an insight, caveat, or question.
Jianfeng Lin (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: